Clinical Trial

Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS

Active, Not Recruiting Phase 4

Record status

This record was last updated October 29, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a proposed randomized prospective study to evaluate both the anti-inflammatory and analgesic effects of a COX-2 inhibitor, celecoxib, in patients with aspirin-exacerbated respiratory disease and Chronic rhinosinusitis following endoscopic sinus surgery. The investigators hypothesize that supplementation with celecoxib can potentially improve surgical outcomes and reduce the postoperative usage of opioid analgesics without an increased risk of bleeding or asthma exacerbation

Protocol Amendment History 7 amendments

This ClinicalTrials.gov record has been amended 7 times since 2019-10-29; most recent amendment 2024-10-25.

Status change: Recruiting → Active, Not Recruiting 2024-10-25

Status change: Not Yet Recruiting → Recruiting 2020-02-20

Trial Details

NCT Number	NCT04147013
Lead Sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Collaborators: Western University, Canada, London Health Sciences Centre
Conditions	Chronic Rhinosinusitis with Nasal Polyps, Aspirin-exacerbated Respiratory Disease
Enrollment	44 participants
Start Date	2020-02-18
Primary Completion	2026-02 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2024-10-29